Corvus制药 CRVS 深 沪
等待开盘 09-23 09:30:00 美东时间
5.995
+0.125
+2.13%
华盛通- 最 高6.04
- 今 开5.89
- 成交量 15.04万股
- 最 低 5.735
- 昨 收 5.87
- 总市值 4.47亿
- 52周最高 10.00
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 2.54
- 委 比 -2.83%
- 总股本 7451.40万
- 历史最高 22.137
- 量 比 0.48
- 振 幅 5.20%
- 历史最低 0.607
- 每 手 1
- 风险率 1.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025
Corvus Pharmaceuticals will host a conference call and webcast on August 7, 2025, at 4:30 pm ET (1:30 pm PT) to discuss business updates and second quarter 2025 financial results. Participants can join via phone by dialing 1-800-717-1738 (US) or 1-646-307-1865 (international), or through the provided link. The live webcast is accessible on the investor relations section of Corvus’ website, with a replay available for 90 days.
07-31 20:01
Corvus Says Partner Angel Pharma's IND Approved By CDE Of China NMPA To Initiate Phase 1b/2 Clinical Trial Of Soquelitinib For Treatment Atopic Dermatitis In China
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel
06-25 20:10
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
Corvus Pharmaceuticals announced the approval of an IND application by Angel Pharma for a Phase 1b/2 trial of soquelitinib in China. The trial, to be conducted by Angel Pharma, will study a 12-week dosing period and a 400 mg once-daily dose for moderate-to-severe atopic dermatitis patients. Corvus co-founded Angel Pharma to develop its pipeline in China. The trial is expected to begin patient enrollment in Q3 2025, with Phase 1b data available in...
06-25 12:00
Corvus Pharma To Present Preclinical Data Highlighting Potential Of Soquelitinib To Treat Systemic Sclerosis At EULAR 2025 Congress
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis will be presented today in a
06-11 19:19
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
Corvus Pharmaceuticals announced the presentation of preclinical data highlighting soquelitinib's potential to treat systemic sclerosis at the EULAR 2025 Congress in Barcelona. The poster, presented by Gonçalo Boleto, M.D., MSc, was selected as a top 10 abstract by EMEUNET. Richard A. Miller, co-founder and CEO of Corvus, emphasized the interest in ITK inhibition for immune-mediated fibrotic diseases and expressed hope to present data on soquelit...
06-11 11:00
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals announced interim Phase 1 data for soquelitinib in moderate to severe atopic dermatitis. Cohort 3 (200 mg BID) showed earlier and deeper responses, with a 64.8% reduction in EASI score at day 28, vs. 54.6% for cohorts 1-2 and 34.4% for placebo. 50% of Cohort 3 patients achieved clinically meaningful itch reduction by day 28. Safety was favorable, with no dose-limiting toxicities. Enrollment has begun in an extension cohort ...
06-04 11:00
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
Corvus Pharmaceuticals announced that its leadership team will participate in one-on-one investor meetings and present a corporate overview at the 2025 Jefferies Global Healthcare Conference in New York on June 5, 2025. The presentation will be available via webcast, accessible through the company's investor relations website for 90 days post-event. Corvus specializes in developing ITK inhibition for cancer and immune disease treatments.
05-28 20:01
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
